Dr. Vassiliki Papadimitrakopoulou on results from the NILE study, for patients with newly diagnosed advanced stage non-squamous NSCLC:
“The most important finding was that liquid biopsy detects… genomic alterations at similar rates with tissue testing, which is standard of care.”
“Rapid turnaround time is of major importance primarily to the patient because the patient with a newly diagnosed non-small cell lung cancer is surrounded by an extremely anxious family and wants to start the therapy tomorrow when they see you.”
Click on the video below to find out more about the key findings of the NILE study.
Visit us online @ guardanthealthamea.com to find out more about Guardant360®, the global leader in liquid biopsy. If you have any queries, send us an email at email@example.com or contact us on WhatsApp: +65 8940 0360.
Guardant360®. Test. Take Action.